DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 9, 2007; DOI: 10.1124/dmd.107.016584


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016584v1
35/10/1759    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, D.-H.
Right arrow Articles by Yun, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.-H.
Right arrow Articles by Yun, C. H.


Received for publication May 16, 2007.
Revised July 1, 2007.
Accepted for publication July 5, 2007.

MECHANISM-BASED INACTIVATION OF CYTOCHROME P450 2A6 BY DECURSINOL ANGELATE ISOLATED FROM ANGELICA GIGAS

Dong-Hyun Kim 1*, Hye Hyun Yoo 2, Min Woo Lee 1, Young Joong Kim 3, Chul Ho Yun 4

1 Korea Institute of Science and Technology 2 Korea Institute of Science and technology 3 Seoul National University 4 Chunnam University

* Address correspondence to: E-mail: dhkim{at}kist.re.kr

Abstract

The inhibition of CYP2A6 by decursinol angelate, a fyranocoumarin isolated from Angelica gigas roots, was examined in human liver microsomes and recombinant CYP2A6. Decursinol angelate moderately inhibited coumarin 7-hydroxylation, but a 20 min preincubation with microsomes and NADPH significantly increased its inhibitory effect (IC50; >20 µM vs. 4.4 µM). A similar inhibition pattern was observed in nicotine C-oxidation, which is also one of the prototype reactions of CYP2A6. Inactivation by decursinol angelate was selective for CYP2A6, and characterized by KI values of 0.99 and 2.42 µM and the kinact values of 0.136 and 0.053 min-1 in microsomes and recombinant CYP2A6, respectively. This inactivation was not protected or restored by nucleophiles, reactive oxygen scavengers or extensive dialysis, but was inhibited by the addition of a competitive CYP2A6 inhibitor, pilocarpine. Furthermore, incubation of CYP2A6 with decursinol angelate in the presence of NADPH resulted in a loss of the spectral CYP2A6 content. An in vitro metabolism study revealed that CYP2A6 oxidized decursinol angelate to the dihydrodiol metabolite, presumably via an epoxide intermediate that might be responsible for the inactivation of CYP2A6. These results collectively demonstrated that decursinol angelate inactivated CYP2A6 in a mechanism-based mode.


Key words: CYP inhibition, CYP2A, enzyme inhibitors, human CYP enzymes, inactivation





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.